Background: Podoplanin is a transmembrane glycoprotein expressed on various normal or neoplastic cells. Some studies have shown that podoplanin promotes the migration and invasion of tumor cells. This study evaluated a podoplanin expression in Odontogenic Keratocysts (OKs) associated or not associated with Nevoid Basal Cell Carcinoma Syndrome (NBCCS) and in Orthokeratinized Odontogenic Cysts (OOCs). Materials and Methods: A total of 50 lesions were obtained in this study, 28 OKs, 18 OKs associated with NBCCS, and 4 OOCs. Immunohistochemical expression of podoplanin in epithelial cells was evaluated using the following score: (a) intensity of immunostaining: (0: absent, 1: weak, 2: moderate, 3: strong, and 4: very strong) and (b) number of positively cells (0: 0%, 1: <25%, 2: 25% to 50%, 3: 50% to 75%, and 4: >75%). The final score was determined by adding the scores of a and b and ranged from 0 to 8 (0: absent, 1 to 4: weak, and 5 to 8: strong). Results: Podoplanin expression was significantly stronger in the basal layer OKs and NBCCS lesions. Further, podoplanin expression was the highest in the suprabasal layer of NBCCS lesions, followed by the suprabasal layers of OK and OOC lesions. Conclusions: Podoplanin expression is different in lesions of different biological behaviors. Podoplanin seems to play a role in cell proliferation and migration.

Aims:To investigate the efficacy of antibacterial photodynamic therapy (APDT) for the treatment of herpes simplex oral and perioral lesions in immunocompetent and oncologic individuals. Methods and Results: APDT was applied in G1 (immunocompetent, n=26) and G3 (oncologic, n=6) with methylene blue 0.01% followed by 660ηm low level LASER in all the lesion area. In G2, immunocompetent patients received Acyclovir cream 50mg/g prescription. Lesion stage, size, edema, and pain degree were obtained at the beginning of the treatment (T0), after 24 hours (T1), 48 hours (T2), 72 hours (T3), and 7 days (T4).Intra-group analyses showed significant improvement in all criteria for G1 and G3 between T0 and T4 (p<0.05), while for G2 no differences were found in lesion stage and pain level between study times (p>0.05). Most of G1 individuals showed crust stage in T2 and T3, while most of G3 individuals presented papule or vesicle at the same times (p<0.05); and G2 presented higher scores of edema in T2 than G1 and G3 at the same time (p<0.05). Conclusions: It is possible to conclude that APDT is an effective adjuvant treatment for HSV oral and perioral infections in both immunocompetent and oncologic individuals.